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Until recently, no point-of-care tool was available for assessing the underlying airway inflam-
mation associated with asthma. Fractional exhaled nitric oxide (FeNO) emerged in the last
decade as an important biomarker for asthma assessment and management. Evidence also in-
dicates that FeNO is most accurately classified as a marker of T-helper cell type 2 (Th2)-medi-
ated airway inflammation with a high positive and negative predictive value for identifying
corticosteroid-responsive airway inflammation.
Thismanuscript evaluates theevidence forFeNOasapredictor ofTh2-mediatedcorticosteroid-
responsive airway inflammation and presents the results of a meta-analysis of three adult studies
comparing asthma exacerbation rates with FeNO-based versus clinically-based asthma manage-
ment algorithms, one of which was not included in a 2012 Cochrane meta-analysis. The primary
purpose of the updated meta-analysis was to evaluate asthma exacerbation rates. The results
demonstrate that the rate of exacerbations was significantly reduced in favor of FeNO-based
asthmamanagement (mean treatmentdifferenceZ0.27; 95%CI [0.42,0.12] aswas the rela-
tive rate of asthma exacerbations (relative rateZ 0.57; 95% CI [0.41, 0.80]).
In summary, FeNO has value for identifying patients with airway inflammationwhowill andwill
not respond to corticosteroids. Importantly, the use of FeNO in conjunction with clinical param-
eters is associated with significantly lower asthma exacerbation rates compared with asthma966 2531; fax: þ1 919 966 7013.
ed.unc.edu (J.F. Donohue).
3 Elsevier Ltd. All rights reserved.
3.02.018
944 J.F. Donohue, N. Jainmanaged using clinical parameters alone. Together these data indicate that FeNO testing has an
important role in the assessment andmanagement of adult asthma. Further studies will continue
to define the exact role of FeNO testing in adult asthma.
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The prevalence of asthma in the United States (US) now
exceeds 8%, and the proportion of asthmatics grew by 15%
in the last decade.1 Not surprisingly, the economic burden
of asthma is also substantial, estimated for 2007 at $56
billion in direct medical costs and loss of productivity.2
These facts underscore the need for more effective ways
to both assess and manage asthma.
It is noteworthy that there have been important changes
in both asthma treatments and asthma guidelines in the
past decade. While the annual death rate for asthma in the
US has declined over the past 15 years,3 the hoped-for
impact of these asthma treatment and asthma guideline
changes on asthma morbidity have not been realized. For
example, the Asthma in America Survey, which was con-
ducted in 1998, demonstrated that the need for acute care
(hospitalization, emergency department visits or other
acute care visits) was common and occurred in approxi-
mately 36% of survey respondents.4 When a similar survey,
the Asthma Insight and Management Survey, was conducted
in 2009, it was found that the need for acute care remained
unchanged, occurring in approximately 34% of adult survey
respondents.4
The reasons for the persistently high levels of asthma
morbidity are multi-factorial and may include, among
others, failure to implement published asthma guidelines,
poor adherence to prescribed medications, differences
between specialist versus primary care management, and
regional differences in access to health care.4 However, it
is also important to note that while routinely available tests
for the evaluation of asthma such as the Asthma Control
Test and spirometry provide some information aboutasthma control, they provide no information about under-
lying airway inflammation, the central pathophysiologic
feature of asthma. This has a number of practical conse-
quences including both over and under diagnosis of
asthma.5,6 In addition, without an objective way to assess
airway inflammation, decisions on which medications to
prescribe to individual patients are often subjective.
Recently, point-of-care measurement of allergic airway
inflammation via assessment of fractional exhaled nitric
oxide (FeNO) has become available. While the measure-
ment of FeNO bridges important gaps in asthma assessment
and management, questions remain about its meaning as a
marker of airway inflammation and its exact role in the
assessment and management of asthma. The purpose of
this paper, therefore, is 3-fold: (1) to evaluate the scientific
and clinical evidence for FeNO as a marker of T-helper cells
type 2 (Th2) inflammation; (2) to evaluate the positive and
negative predictive value of FeNO for identifying
corticosteroid-responsive airway inflammation; and (3) to
present the results of an updated meta-analysis evaluating
asthma exacerbation rates with FeNO-based versus
clinically-based asthma management algorithms.
FeNO as a marker of Th2-mediated airway
inflammation
Asthma is a heterogeneous, chronic disease characterized
by two fundamental and interrelated abnormalities: airway
inflammation and airway hyper-responsiveness. The airway
inflammation and hyper-responsiveness associated with
asthma can be triggered by exercise and numerous exoge-
nous factors such as aeroallergens, infections, cigarette
smoke and other irritants. In allergic asthma, which is the
Utility of exhaled nitric oxide in adult asthma 945underlying cause of asthma for up to 80% of children and
approximately 50% of adults,7e9 airway inflammation re-
sults from the activation of mast cells and antigen-specific
Th2 cells, resulting in the production of cytokines, including
interleukin (IL)-4, IL-5 and IL-13.10 In turn, IL-4 and IL-13
cause epithelial inducible nitric oxide synthase (iNOS)
expression to be upregulated via signal transducer and
activator of transcription (STAT)-6, a process which is
corticosteroid sensitive.11 Thus, exhaled NO is a direct
signal of the Th2-mediated, pro-inflammatory cytokine
mechanisms of central importance in the pathophysiology
of allergic airway inflammation.
The 2011 American Thoracic Society (ATS) guideline for
the use of FeNO in clinical practice characterized FeNO as a
marker of eosinophilic airway inflammation.12 However,
recent clinical information suggests that FeNO production is
more accurately defined as a marker of Th2-mediated
inflammation, which often includes airway eosinophilia,
rather than eosinophilic inflammation per se. The dissoci-
ation between FeNO and eosinophilic inflammation was
highlighted by the results of recent studies with anti-IL5
and anti-IL13. In the first study, systemic treatment with
mepolizumab, an anti-IL-5 monoclonal antibody, was shown
to significantly reduce blood and sputum eosinophil counts,
but it had no effect on FeNO levels.13
In the second study, systemic treatment with leb-
rikizumab, an anti-IL-13 monoclonal antibody, had no ef-
fect on peripheral blood eosinophils but was associated
with significant reductions in FeNO levels, especially
among subjects with high baseline periostin levels.14
Additionally, treatment with anti-IL-13 was associated
with significant improvements in FEV1 in the overall pop-
ulation and a 60% reduction in exacerbation rate
compared with placebo (p Z 0.03) among the subgroup of
patients defined as the high-Th2 subgroup. Hence, while
increases in airway eosinophils and increases in FeNO
often occur concurrently, the cytokines that regulate in-
duction of iNOS via STAT-6 are separate from those regu-
lating eosinophil traffic through the airways in asthma,
with the result that FeNO and eosinophilic inflammation
may be dissociated.
Albeit airway inflammation is central to the pathophys-
iology of asthma, it is recognized that the type, extent and
severity of inflammation is not uniform and varies among
patients with asthma. Specifically, asthma patients differ
with respect to clinical characteristics, underlying airway
inflammation cell type, and response to inhaled cortico-
steroid (ICS) treatment.15 For example, the presence of
Th2-mediated airway inflammation, eosinophilia, elevated
FeNO levels, and responsiveness to ICS is common in both
pediatric and adult asthma. However, some asthma pa-
tients have airway inflammation that is characterized by
airway neutrophilia and lower FeNO levels. Such patients
are often less responsive to ICS.16,17 Nonetheless, at least
one study has reported that FeNO levels can help predict
ICS response even among patients with neutrophilic asthma
in whom airway eosinophilia is absent.18 Importantly,
traditional parameters such as symptoms and lung function
are not able to distinguish these patients, while biomarkers
such as FeNO can help distinguish patients with
corticosteroid-responsive asthma from those whose asthma
is unlikely to be corticosteroid responsive.Exhaled nitric oxide and the assessment of
corticosteroid-responsive airway inflammation
FeNOhas been shown to beuseful as an adjunct to traditional
methods for the assessment of patients with suspected but
undiagnosed asthma. In this regard, FeNO levels have been
shown to correlate well with sputum eosinophils,19e21 blood
eosinophils,22 serum eosinophilic cationic protein,22 and
immunoglobulin E levels.23 However, FeNO, a marker of
Th2-mediated airway inflammation, is particularly useful
as an indicator of ICS-responsive airway inflammation and,
perhaps more importantly, for identifying airway inflamma-
tion thatwill not respond to corticosteroids. These principles
are reflected in the 2011 ATS guidelines, which recom-
mended the use of normal ranges and clinical cut points
when interpreting FeNO values. Specifically, the ATS guide-
lines suggest that a FeNO less than 25 ppb (<20 ppb in chil-
dren) is a strong indicator that responsiveness to
corticosteroids is unlikely, while a FeNO greater than 50 ppb
(>35 ppb in children) is a strong indicator that responsive-
ness to corticosteroids is likely.12
While not directly related to the FeNO cut points that
have been defined for patients with established asthma,
FeNO levels in non-asthmatic children and adults have
recently been evaluated using data from the National Health
and Nutrition Examination survey (NHANES) 2007e2010 data
set. From this data set, the 95th percentile for FeNO was
determined to be 39 ppb (ages 12e80 years) and 36 ppb
(ages < 12 years), and FeNO levels above these values are
indicative of airway inflammation.24 Importantly, the au-
thors found that predictive equations did not adequately
explain the variation observed in FeNO in the general popu-
lation. This observation provides further support for the
recommendation of the ATS that clinical cut points rather
than predictive equations be used when interpreting FeNO
values.
The robust evidence for the positive and negative pre-
dictive value (PPV, NPV) of FeNO for identifying
corticosteroid-responsive Th2 airway inflammation was
reviewed recently by Taylor,25 who summarized studies
evaluating subjects with various airway diseases (e.g.,
asthma, chronic obstructive pulmonary disease [COPD],
chronic cough) and varying prior asthmamedication histories
(e.g., steroid-naı¨ve asthma, severe asthma on ICS). These
studies (Table 1) demonstrate three key points: (1) FeNO has
greater value for predicting ICS responsiveness than con-
ventional measures such as peak flow rates, spirometry, and
bronchodilator responsiveness26,27; (2) the NPV of FeNO for
assessing asthma and identifying ICS non-responsiveness is
very high across the asthma studies (91e95%) at cut points of
FeNO that generally range from 20 to 30 ppb26e32; and (3) the
PPV of FeNO for assessing asthma and identifying ICS
responsiveness is also high across asthma studies (79e82%)
when the FeNO cut point is 47 ppb or higher.27,29
The PPV and NPV of FeNO for ICS responsiveness is further
supported by results of bronchial hyper-responsiveness
(BHR) studies. BHR can be assessed using direct stimuli
such as MCH or using indirect stimuli such as mannitol or
adenosine monophosphate (AMP). AMP and mannitol cause
release of inflammatory mediators from inflammatory cells
and the respiratory epithelium that, in turn, cause
Table 1 Selected data indicating the performance characteristics for baseline measurements of exhaled nitric oxide FeNO as
a predictor of different clinical outcomes.
Indication/clinical
outcome of interest
Sensitivity
(%)
Specificity
(%)
Positive
predictive
value (%)
Negative
predictive
value (%)
Reference
Diagnosis of asthma in
patients with chronic
non-specific respiratory
symptomsa,b
88 (20 ppb) 79 (20 ppb) 70 (20 ppb) 91 (20 ppb) Smith et al. (2004)26
Diagnosis of asthma in
patients with chronic
cough
75 (30 ppb) 87 (30 ppb) 60 (30 ppb) 93 (30 ppb) Chatkin et al. (1999)28
88 (40 ppb) 83 (40 ppb) 79 (50 ppb) 94 (20 ppb) Kowal et al. (2009)29
86 (32 ppb) 76 (32 ppb) 47 (32 ppb) 95 (32 ppb) Oh et al. (2008)30
Steroid responsiveness
(non-specific respiratory
symptoms)c,d
82 (47 ppb) 91 (47 ppb) 82 (47 ppb) 91 (47 ppb) Smith et al. (2005)27
Steroid responsiveness
(cough)c
NA NA 88 (35 ppb) 91 (25 ppb) Hahn et al. (2007)31
Steroid responsiveness
(COPD)c,e
29 (50 ppb) 96 (50 ppb) 67 (50 ppb) 87 (25 ppb) Dummer et al. (2009)69
80 (35 ppb) 67 (35 ppb) 57 (35 ppb) 86 (35 ppb) Akamatsu et al. (2011)70
Prediction of likely steroid
response in patients with
‘difficult asthma’ already
taking ICS
88 (30 ppb) 91 (30 ppb) 88 (30 ppb) 91 (30 ppb) Perez de Llano
et al. (2010)32
BOS in lung transplantation 94 (20 ppb) 82 (20 ppb) 69 (20 ppb) 97 (20 ppb) Neurohr et al. (2011)71
In general, and similar to D-dimer and pro-BNP, FeNO is a better negative predictor when values are low/normal (<25 ppb in adults,
<20 ppb in children) than it is a positive predictor when values are high. Thus it may be better used to exclude rather than include the
outcome in question. The data quoted in the table are for the single optimum cut point (figures in parentheses) unless data for additional
(low and high) cutpoints were available in the papers cited.
Adapted from Ref. 25. ª 2012, with permission from the Institute of Physics.
a A diagnosis of non-atopic asthma (often ‘neutrophilic’) may still be made if the patient has relevant symptoms, abnormal spirometry
and/or airway hyper-responsiveness but a low/normal FeNO.
b The performance characteristics of FeNO in this context were similar to those of induced sputum eosinophil counts, and better than
spirometry and peak flow variability. See Smith et al. (2004).26
c Patients assessed at first presentation, and steroid naı¨ve.
d The endpoint was reduction in AHR, i.e. an increase in PC20/AMP of >2 doubling doses.
e The endpoint was improvement in FEV1 of >0.21.
946 J.F. Donohue, N. Jainbronchoconstriction. It can thus be anticipated that FeNO
levels and BHR to indirect stimuli such as AMP and mannitol
would be correlated. Along these lines, Sverrid et al. has
shown that the PPV of mannitol was substantially higher
(90.4%) than for MCH for diagnosing asthma (48.6%).33
Importantly, patients with BHR to mannitol had substan-
tially higher FeNO levels (47 ppb) than those without BHR to
mannitol (19 ppb)33 and, as noted previously, ICS respon-
siveness is high (82%) when the FeNO cut point is 47 ppb or
higher.27
Finally, although the mechanism of action of MCH is to
produce bronchoconstriction directly rather than via the
release of inflammatory mediators, its use in conjunction
with FeNO can be helpful in assessing asthma and ICS
responsiveness. For example, Schleich et al. demonstrated
that a FeNO > 34 ppb had a PPV of 88% for identifying a PC20
to MCH of <16 mg/ml.34 Similarly, Schneider et al. found
that the PPV of FeNO for identifying a PC20 to MCH of
16 mg/ml was 80% when the FeNO level was >46 ppb.35
Importantly, the authors indicated that in subjects with
non-specific respiratory symptoms whose FeNO is  12 ppb,
asthma can effectively be excluded and that bronchopro-
vocation tests are unnecessary.Exhaled nitric oxide and asthma management
Because FeNO levels predict ICS responsiveness, and, more
importantly, lack of ICS responsiveness, the ATS guidelines
recommend using FeNO in monitoring airway inflammation
in patients with established asthma.12 Nonetheless, when
interpreting FeNO levels, factors that can confound FeNO
levels need to be considered.12,36 These include acute viral
airway infection and allergic rhinitis, both of which may
elevate FeNO levels.11,12,36 Notably, chronic rhinosinusitis
may be associated with elevated FeNO levels that may not
be responsive to corticosteroid administration.36e38 More-
over, FeNO levels are reduced by smoking11 but may be
increased by eating.12 Patients should thus refrain from
eating and drinking for 1 h before FeNO testing as a nitrate-
rich diet may increase FeNO levels. Additionally, FeNO
should be measured before spirometry and bronchodilator
administration as both may affect FeNO levels, though the
effect is small.12,39
With these caveats in mind, the number of studies
comparing FeNO-based asthma management algorithms
with standard asthma management algorithms in adults and
Utility of exhaled nitric oxide in adult asthma 947children has been relatively limited. Petsky et al. published
a meta-analysis of studies evaluating FeNO40 or FeNO and
sputum eosinophils for the management of patients with
asthma in 2012.41 Based on the meta-analysis results, the
authors concluded that the use of FeNO in clinical practice
cannot be recommended and that future studies are
needed.40,41
In evaluating the conclusions of these papers, it must
be noted that the algorithm study by Powell et al.,42
published in 2011, was not included in either publica-
tion. The Powell study was a randomized controlled trial
of up to 6 months duration in which 220 pregnant women
with asthma were randomly assigned to a FeNO-based
management group (n Z 111) or a clinical management
group (n Z 109). This study showed a significantly lower
exacerbation rate in the FeNO group (0.288 exacerbations
per pregnancy) compared with the group managed using
clinical parameters alone (0.615 exacerbations per preg-
nancy; P Z 0.001).42
The primary outcome of both the Cochrane systematic
review and the Petsky meta-analysis was the number of
participants who had asthma exacerbations during follow-
up.40,41 Fig. 1 shows the results for the number of exacer-
bations from the original Cochrane meta-analysis.43e47 Of
note, the number of subjects with asthma exacerbations
was numerically lower for subjects managed using FeNO
compared with subjects managed using clinical parameters
alone for all of the studies except for the Smith study.43
In considering these data, it must be recognized that the
number of patients having asthma exacerbations is not the
most appropriate endpoint for assessing exacerbations, as
it does not take into consideration subjects who may have
multiple exacerbations during the course of a study. In this
regard, the time to first asthma exacerbation and/or
asthma exacerbation rates are considered by the NIH to be
the most appropriate outcomes for assessing asthmaFigure 1 Number of subjects who had 1 exacerbation over t
exhaled nitric oxide (FeNO) levels versus traditional methods for
permission from the BMJ Publishing Group.exacerbations.48 For this reason, the data from FeNO
studies conducted in adults (the Shaw44 and Smith43 studies
from the original meta-analysis plus the Powell study42)
have been analyzed for the endpoint of asthma exacerba-
tion rates. The analysis was conducted using the standard
approach that was used in the Cochrane meta-analysis.40,41
This analysis demonstrates that the rate of exacerbations
was substantially reduced in favor of the FeNO-based
asthma management strategy (0.27 [0.42, 0.12])
(Fig. 2). Moreover, when the data is expressed as a relative
rate, the rate of asthma exacerbations was more than 40%
lower with the FeNO-based asthma management strategy
compared with the control asthma management strategy
(0.57 [0.41, 0.80]) (Fig. 3).
As with all treatments or treatment approaches used in
patients with asthma (children and adults), it is important to
consider the risk:benefit ratio. For a comparison of FeNO-
guided asthma management with asthma managed using
clinical parameters alone, the corticosteroid requirements
for each management strategy must be assessed. ICS dose at
the end of the study for the FeNO and control strategies was
similar or lower for all of the algorithm studies except for the
study by Szefler et al. (Table 2).47 The study by Szefler
et al.,47 however, did not permit non-compliant subjects to
be randomized, and the subjects had high levels of asthma
control at randomization. Additionally, FeNO levels could be
used to increase ICS dose even when asthma was otherwise
controlled, but the ICS dose could not be reducedwhen FeNO
levels were low unless every other asthma parameter was
also controlled. Thus it is not surprising that ICS doses
were higher in the FeNO group. In other studies in children
and adults where requirements for high medication
compliance and control were not study entry requirements,
ICS doses were either similar for the FeNO and control stra-
tegies42,45,46 or were lower in favor of the FeNO strategy
(Table 2).43,44he study period in adult algorithm-based clinical trials using
asthma management. Reprinted from Ref. 41. ª2012, with
FeNO Strategy Control Strategy 
Study 
Exacerbation 
Rate 
Total No. 
Patients 
Exacerbation 
Rate 
Total No. 
Patients Weight 
Mean Difference 
 (95% CI) 
Shaw 2007 0.33 52 0.42 51 24.7% -0.09 (-0.38, 0.20) 
Smith 2005 0.49 46 0.9 48 5.4% -0.41 (-1.05, 0.23) 
Powell 2011 0.288 111 0.615 109 69.9% -0.33 (-0.48, -0.18) 
Combined 0.31 209 0.58 208 100.0% -0.27 (-0.42, -0.12) 
Mean Difference 
 -1.0         -0.5           0           0.5         1.0
Favors FeNO        Favors Control 
Figure 2 Rate of asthma exacerbations (number of exacerbations per patient over the study period) in adult algorithm-based
clinical trials using exhaled nitric oxide (FeNO) levels versus traditional methods for asthma management. Data from the study
by Powell et al. have been added to data from adult studies included in the original Petsky et al. meta-analysis (i.e., Shaw et al.
and Smith et al.). DerSimonian and Laird random effects model used for the meta-analysis. Test for heterogeneity: Q Z 2.2 with
p Z 0.33 and I2 Z 9.7%, indicating little if any evidence of heterogeneity.
948 J.F. Donohue, N. JainFinally, although published after the 2012 Petsky meta-
analysis,41 one additional study in adults has recently been
published. Specifically, Calhoun et al. conducted a study in
which the following treatment approaches were compared:
physician-based management, biomarker-based manage-
ment using FeNO and symptom-based management (i.e.,
when a patient had symptoms, he/she received a dose of an
ICS as well as a short-acting beta agonist).49 There was no
difference in time to treatment failure among the three
groups. However, this finding is potentially related to the
very mild cohort included in this study. The patients eval-
uated had very well controlled asthma as evidenced by the
fact that approximately 40% of subjects required no ICS at
any given clinic visit. As such it is not surprising that a
biomarker such as FeNO, which identifies inflammation that
might be discordant from symptoms, was not of benefit.
In summary, studies comparing FeNO to usual clinical
management of asthma generally indicate that exacerba-
tion rates are reduced while ICS requirements are gener-
ally neutral. The preponderance of data thus indicates that
the risk:benefit ratio is positive for FeNO and indicate that
FeNO testing has an important role in the assessment
and management of adult asthma. Further studies willFeNO Strategy Control Strategy
Study
Exacerbation
Rate
Total No. 
Patients
Exacerbation 
Rate Patients
Shaw 2007 0.33 52 0.42 51
Smith 2005 0.49 46 0.9 48
Powell 2011 0.288 111 0.615 109
Combined 0.32 209 0.59 208
Figure 3 Relative rate of asthma exacerbations (number of exac
based clinical trials using exhaled nitric oxide (FeNO) levels versu
study by Powell et al. have been added to data from adult studies
et al. and Smith et al.). DerSimonian and Laird random effects mod
with p Z 0.46 and I2 Z 0%, indicating no evidence of heterogeneicontinue to define the exact role of FeNO testing in adult
asthma.
Additional uses for exhaled nitric oxide in the
management of inflammatory airway diseases
A thorough review of the clinical applications of FeNO testing
has recently beenpublished.25 Nonetheless, three additional
areas where FeNO testing is particularly relevant are
the identification of “at risk” patients, assessing cortico-
steroid adherence/compliance, and the assessment of
airway inflammation in patients with COPD or the overlap
syndrome.
Identification of ‘at-risk’ patients
A number of recent studies have examined the role for
FeNO in identifying patients at risk for future impairment,
such as the development of an asthma exacerbation. Zeiger
et al., in a cross-sectional study of 304 patients with
established asthma, demonstrated that the likelihood of
having 7 short-acting beta-agonist canisters dispensed orWeight
Relative Rate
(95% CI)
29.4% 0.79 (0.43, 1.44)
10.9% 0.54 (0.20, 1.46)
59.7% 0.50 (0.33, 0.76)
100.0% 0.57 (0.41, 0.80)
RR
0.1 0.2     0.5       1.0       2        5  10
Favors FeNO Favors Control
erbations per patient over the study period) in adult algorithm-
s traditional methods for asthma management. Data from the
included in the original Petsky et al. meta-analysis (i.e., Shaw
el used for the meta-analysis. Test for heterogeneity: QZ 1.6
ty.
Table 2 Mean ICS dose in patients managed with a FeNO strategy compared with clinical management.
FeNO strategy Control strategy Mean diff.
Mean ICS
dose
Total no.
patients
Mean ICS
dose
Total no.
patients
Subgroup
weight
Overall
weight
FeNO strategy e control
(95% CI)
Adults
Shaw 200744 557 52 895 51 31.3% 13.8% 338.0 (676.6, 0.4)
Smith 200543 740 46 1282 48 32.4% 14.7% 542.0 (847.9, 236.1)
Powell 201142 738.9 72 631.6 76 36.4% 18.7% 107.30 (69.2, 283.8)
Combined 170 175 100.0% 47.2% 242.09 (671.0, 186.8)
PEDS
de Jongste 200945 474.67 75 444.37 71 34.4% 18.1% 30.3 (166.7, 227.3)
Pijnenburg 200546 935.4 39 910.4 46 21.4% 15.4% 25.0 (259.2, 309.2)
Szefler 200847 1120 276 880 270 44.2% 19.3% 240.0 (86.9, 393.1)
Combined 390 387 100.0% 52.8% 121.9 (32.2, 276.0)
Overall 560 562 100.0% 50.7 (259.4, 158.0)
Utility of exhaled nitric oxide in adult asthma 9492 courses of oral corticosteroids for asthma exacerbations
in the follow-up year was 2.26 and 3.26 times more
frequent, respectively, for subjects whose FeNO values
were >300% predicted.50 Similarly, Gelb et al. showed that
the combined use of FeNO and FEV1 was useful for identi-
fying patients at risk for future development of an asthma
exacerbation.51 Among 53 patients followed for a period of
18 months, no subject with an FEV1 > 76% predicted and a
FeNO < 28 ppb had an asthma exacerbation, whereas 85%
of subjects with an FEV1 76% predicted and a FeNO
28 ppb developed an asthma exacerbation.51 Moreover,
studies in both adults and children have shown that FeNO is
useful in identifying patients who will develop a loss of
asthma control following a reduction in, or cessation of,
ICS.52,53 It is important to note, however, that changes in
FeNO levels may not be as useful as changes in sputum
eosinophils for predicting loss of asthma control following
reduction/cessation of ICS use.54,55 Additional studies in
this area are clearly needed. However, the available data
generally suggests that FeNO is useful in identifying pa-
tients at risk for future impairment or for developing loss of
asthma control during reduction/cessation of ICS
treatment.Assessment of corticosteroid treatment compliance
In addition to being an indicator of corticosteroid-
responsive Th2 airway inflammation, FeNO is also useful
for assessing adherence with corticosteroid therapy in pa-
tients with established asthma. This was first identified
more than a decade ago by Beck-Ripp and colleagues, who
evaluated FeNO levels in children in a placebo-controlled
study following sequential changes in budesonide.56 The
authors demonstrated that FeNO, but not conventional lung
function tests, were able to differentiate between children
treated with or without budesonide. This study also showed
a strong correlation between FeNO levels and compliance
to budesonide. In another study conducted in 30 children
7e17 years of age with persistent asthma, a significant
correlation between FeNO levels and corticosteroidcompliance was demonstrated (r Z 0.76, p Z 0.001).57
This type of information is critical to asthma treatment
decision making in practice. It has been established that
corticosteroid compliance rates are, on average, below 50%
(range 20e73%).58 Thus, FeNO can help distinguish patients
whose lack of asthma control is due to corticosteroid non-
compliance and help avoid overuse of more costly and un-
necessary asthma medications.Assessment of airway inflammation in patients with
COPD or the overlap syndrome
Asthma can coexist with COPD, particularly in older adults,
a condition labeled the overlap syndrome. In data from
NHANES (1988e1994) and the UK General Practice Research
Database (1998), Soriano et al. determined that a
concomitant diagnosis of asthma and COPD may be found in
as many as 50% of patients aged 50 years,59 although
other studies have estimated the incidence to be in the
range of 20e30%.60,61 It is considered likely that some
asthmatics develop COPD in addition to asthma as they age
due to the cumulative harmful effects of cigarette smok-
ing.62 In contrast to patients with the overlap syndrome,
patients who have chronic bronchitis and/or emphysema,
which is almost always caused by smoking, are character-
ized by airflow obstruction that is often irreversible and
airway inflammation that is often not Th2-mediated.61
It is important to note that no ICS is currently approved
for use as a monotherapy for COPD in the US. Moreover,
while several ICS/long-acting beta agonist combination
products have been approved for use in COPD, the inci-
dence of ICS-related morbidity such as osteoporosis and
pneumonia are increased in COPD patients treated with
ICS-containing products.63e65 It is in this context that FeNO
may help identify patients with allergic airway inflamma-
tion who will have a beneficial response to treatment with
an ICS and those who will not.66e69 Along these lines, Antus
et al. demonstrated a significant correlation between FeNO
levels and improvements in FEV1 in patients with COPD
exacerbations following treatment with systemic
950 J.F. Donohue, N. Jaincorticosteroids and bronchodilators.66 Similarly, Kunisaki
et al. found a significant difference in FeNO levels among
COPD patients who did versus did not respond to a 4-week
trial of ICS with a 200 ml increase in FEV1 (46.5 ppb versus
25 ppb).67 While additional studies are needed, FeNO has
potential as a tool to help identify those patients with COPD
or the overlap syndrome for whom the risk:benefit ratio for
treatment with an ICS-containing product will be positive.
Conclusion
In summary, asthma is a costly and burdensome disease,
and there is a need for effective ways to both identify those
who will benefit from corticosteroid treatment and those
who will not. Until recently, there has been no point-of-
care tool for use in assessing the underlying airway
inflammation associated with asthma. However FeNO
testing has emerged as a non-invasive, inexpensive, reliable
indicator of corticosteroid-responsive Th2-mediated
inflammation for use in the assessment and management of
asthma.
Does FeNO assist clinicians in treatment decision making
such as initiating or increasing ICS therapy, and can these
decisions have a beneficial impact on asthma outcomes?
Taking into account the accumulated evidence, including
the data from new analyses in this paper, the answer to
both questions is “yes.”
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